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Abstract
β-Thalassemia and HbE, each, is a syndrome resulted from quantitative and qualita-
tive defects of β-globin chain, respectively. In addition to history retrieve and physical 
examination, diagnosis of these disorders requires laboratory information. Laboratory 
tests that are conventionally performed to diagnose the β-thalassemia and HbE are clas-
sified into two groups, based on the purposes, including the screening tests and confir-
matory tests. The screening tests are aimed to screen for carriers of the β-thalassemia 
and HbE, while confirmatory tests are the tests performed to definitely diagnose these 
disorders. This chapter will explain all of these tests, the information of which will be 
useful for those who are working and interested in the β-thalassemia and HbE.
Keywords: β-thalassemia, HbE, screening tests, confirmatory tests, 
thalassemia carrier, HbE carrier, β-thalassemia disease
1. Introduction
1.1 Thalassemia and hemoglobinopathies
Thalassemia is a type of anemia caused by reduction or absence of globin chain 
synthesis, which results in imbalanced-globin chain synthesis; the major pathogen-
esis of the disease. The unaffected globin chains continuing to be synthesized at the 
normal synthetic rate tend to form homotetramers and aggregation that can harm 
the red blood cells both at young and mature stages. The α-globin chain aggregation 
formed in β-thalassemia causes ineffective erythropoiesis due to oxidative stress. The 
γ- and β-globin chain homotetramer (γ4, β4) formed in α-thalassemia harm mature 
erythrocytes. The γ4 or Hb Bart’s has very high oxygen affinity and inhibits oxygen 
release from erythrocytes which, in turn, results in tissue anoxia. The β4 or HbH is an 
unstable hemoglobin and precipitates easily under the stress condition in the body. 
Once precipitates, the erythrocytes are removed by the RE system resulting in anemia.
Severe thalassemia cases suffer from chronic and marked anemia with life rely-
ing solely on blood transfusion. Anemia causes expansion of bone marrow, leading 
to osteoporosis and changes of bone structure. Blood transfusion and hemolysis 
cause iron overloading state in the body which causes several complications such as 
heart disease, growth retardation, diabetes mellitus, and infection.
Thalassemia is considered the most common autosomal single-gene disorder 
worldwide. It can be found in more than 150 countries with an estimated carrier 
frequency of about 7%. The Mediterranean region, certain parts of North and West 
Africa, Middle East, Indian subcontinent, Southern Far East, and South East Asia 
have the highest prevalence of the disease [1].
Beta Thalassemia
2
In contrast to the thalassemia, hemoglobinopathy is an inherited disorder of 
hemoglobin productions characterized by production of abnormal hemoglobin or 
hemoglobin structural variants occurring from genetic alterations including point 
mutations, deletions or insertion of the normal globin genes. The well-known 
abnormal hemoglobins in the world are HbS, which is common in western countries 
as well as in the Middle East and HbE, which is common in Southeast Asia [2].
1.2 Types of thalassemia and hemoglobinopathies
Two major types of thalassemia are found across the world consisting of 
the α- and β-thalassemia. The α-thalassemia is further sub-divided into two 
types: α-thalassemia 1 or αO-thalassemia and α-thalassemia 2 or α+-thalassemia. 
Gene deletion is the leading cause of α-thalassemia. In α-thalassemia 1, two 
α-globin gene in-cis on chromosome 16 are deleted, while only one α-globin 
gene is absent in the α-thalassemia 2 [3]. In addition, there are two types of 
β-thalassemia; βO-thalassemia and β+-thalassemia. In contrast to α-thalassemia, 
mutations on the β-globin gene are found in the majority of the β-thalassemia 
patients [4].
Two broad types of hemoglobinopathies or structural variants are also found; 
α- and β-hemoglobinopathies. To date, approximately 1358 structural variants are 
described (http://globin.bx.psu.edu), around 90% of which are involved in the β, γ, 
and δ-globin chains and around 60% involves the α-globin chain. The most impor-
tant β-globin hemoglobinopathies are HbS (α2β2
6Glu−Val) and HbE (α2β2
26Glu−Lys). 
Hb E is found around the world and accounts for approximately 13–17% on the 
population of Thailand, especially in the Thai-Laos-Cambodian boundary or “Hb E 
triangle” where more than 32–60% of the people carry HbE gene [5].
1.2.1 β-Thalassemia
The β-thalassemia is a diverse group of disorders of hemoglobin synthesis which 
is characterized by reduced or absent β-globin chain synthesis. There are two main 
types of β-thalassemia: βO-thalassemia in which no β-globin chain is produced and 
β+-thalassemia in which some β-globin is produced but less than normal.
β0-Thalassemia is severe β-thalassemia with no production of β-globin chain. It is 
mainly caused by point mutations in coding region (exon) or exon-intron junction 
of β-globin gene which lead to premature stop codon or generation of abnormal 
β-globin mRNA. The end results of these abnormalities are absence of the β-globin 
chain production [6]. In Thailand, at least three common mutations in the β-globin 
gene are of this category. They comprise A-T substitution at codon 17 (CD17: A-T) 
which creates premature stop codon, the TTCT-deletion at codons 41/42 (CD41/42: 
−TTCT) which causes reading frameshift and premature stop codon at codon 59 
instead of codon 147, the G-T substitution at IVSI-nt1 which leads to abnormal 
splicing of immature β-mRNA and results in no production of normal β-mRNA. In 
general, thus, genotype of heterozygote is written as β0/βA and that for homozygote 
as β0/β0 [2, 7–9].
β+-Thalassemia is a milder form of β-thalassemia in which some β-globin chains 
are still produced. The majority of cases possess point mutations outside exons, 
especially in the promoter region. The mutations of β-globin gene leading to the 
β+-thalassemia include mutations at ATA box (nt-28, nt-29 or nt-30 from cap site), 
CACCC element (nt-86 to nt-90 from cap site), and mutations in introns or exons 
of gene to produce new splice site to race in RNA splicing process, as mutation in 
IVS2-nt654 (C-T) and mutation of IVS1-nt5 (G-C) [2, 6]. The genotypes were β+/βA 
and β+/β+ for heterozygote and homozygote consecutively.
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1.2.2 β-Hemoglobinopathies
β-Hemoglobinopathies are characterized by the production of abnormal 
β-globin chains due to changes or mutations (missense mutations) on the β-globin 
gene. Two abnormal β-globin chains then assemble with two normal α-globin 
chains to form abnormal hemoglobin or β-structural variants. These abnormal 
hemoglobins generally have different electrophysical properties from their normal 
counterparts; that is, due to the molecular conformational alteration. In theory, 
synthetic rate of the abnormal β-globin chain should be normal. However, some 
are produced in reduced rate, thus producing a phenotype resembling the β+-
thalassemia. To date, there are more than 737 β-globin structural variants reports 
across the world (http://globin.cse.psu.edu/).
1.3 Hemoglobin E
HbE is abnormal hemoglobin resulted from the G-A substitution at codon 26 of 
β-globin gene. This missense mutation partially activates a cryptic splice site toward 
the 3′ end of exon 1, resulting in a proportion of abnormally splice mRNA. Thus, 
less βE globin is synthesized, leading to a mild thalassemia phenotype. HbE is 
becoming the common β-globin structure variant across the world as a result of 
migration and inter racial marriage [2, 10]. It has been realized to be the hallmark of 
Southeast Asian region. In Thailand, HbE is very common accounting for approxi-
mately 8–70% of population [11].
1.4 Inheritance of genes for β-thalassemia and HbE
Gene for β-thalassemia and HbE is transmitted within the family from parents 
to descendants in an autosomal recessive fashion. Thus, those who are heterozygous 
for abnormal β-gene are clinically asymptomatic and called β-thalassemia carrier or 
β-thalassemia trait. Those who are heterozygote for HbE gene (βE) are also clini-
cally asymptomatic and called HbE carrier or HbE trait. However, homozygote or 
compound heterozygote of the β-thalassemia gene and/or HbE gene are clinically 
affected and suffer from chronic anemia with some life-threatening complication. 
Therefore, accurate diagnosis of carriers of the β-thalassemia and HbE as well as the 
disease is important.
1.5 Problem of β-thalassemia and HbE
The carriers of β-thalassemia and HbE do not have clinical burden as they are 
clinically normal and have normal quality of life. However, if the β-thalassemia 
carriers get married with the HbE carriers, they will have 25% chance of producing 
the HbE/β-thalassemia babies. The HbE/β-thalassemia or sometimes called the 
β-thalassemia/HbE disease is a thalassemia syndrome that presently is known to be 
clinically heterogeneous [10–12]. Some patients are very mild, while some are very 
severe. The severe cases always required regular blood transfusion which always 
ends up with iron overloading condition. Without proper management of this iron 
overloading, several fatal complications occur, leading to low quality of life and, 
finally, pre-death at young age.
1.6 Diagnosis of β-thalassemia and HbE
The diagnosis of β-thalassemia and HbE involves both clinical and laboratory 
investigations. Clinical data can only identify the affected patients, but cannot 
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definitely identify types of thalassemia the patients are suffering. Laboratory data 
thus help define specific types of thalassemia disease of those affected individu-
als. For the carriers, as they are clinically normal, clinical data are of no use. Only 
laboratory data can define β-thalassemia and HbE carriers.
Conventionally, the laboratory tests for diagnosis of β-thalassemia and HbE 
include screening tests and confirmatory tests. Initial screening tests are defined 
as techniques that are simple and relatively low cost, which can indicate the possi-
bility of having thalassemia. These tests should involve the least sample pretreat-
ment and rapid sample preparation and may not need special instrumentation. 
This would lead to low cost and high sample throughput analysis. The screening 
tests, however, cannot provide the information on the exact type of thalassemia 
of the positive persons. Positive samples need further confirmatory test while 
negative samples can be eliminated from further complicated and expensive 
testing.
The screening tests for β-thalassemia carriers comprise one-tube osmotic fragil-
ity test (OFT) and automated red blood cell indices (mean corpuscular volume; 
MCV, mean corpuscular hemoglobin; MCH, and red cell distribution width; RDW). 
Screening tests for HbE carriers are composed of all tests performed to screen for 
the β-thalassemia carrier plus the specifically established for HbE screen such as 
dichlorophenolindophenol precipitation (DCIP) test or HbE tube test or HbE test 
[13–16]. These screening tests, however, cannot provide the information on the 
exact type of thalassemia of the positive persons.
The purpose and methodologies of confirmatory tests for β-thalassemia and 
HbE are identical. The confirmatory tests must be highly specific in order to obtain 
the correct diagnosis of carriers of β-thalassemia and HbE as well as the disease 
state of HbE/β-thalassemia and homozygote or compound heterozygote of the 
β-thalassemia gene. The confirmatory tests include;
• Hemoglobin studies: Tests for hemoglobin studies include cellulose acetate 
electrophoresis, microcolumn chromatography, alkaline denaturation test, 
cation-exchange high performance liquid chromatography (HPLC) [17–19], 
cation-exchange low pressure liquid chromatography (LPLC) [20–22], capil-
lary zone electrophoresis (CZE) [23–27], sandwich enzyme linked immu-
nosorbent assay (ELISA) for Hb F [28], Hb Bart’s [29] and Hb A2 [30], flow 
cytometric analysis of F cells [31], and immunochromatographic strip (IC 
strip) test for Hb Bart’s [32].
• DNA analysis: Tests for analysis of β-globin gene mutations include multiplex 
allele-specific polymerase chain reaction (MAS-PCR) [29], amplification 
refractory mutation system (ARMS)-PCR [33], mutagenically separated (MS)-
PCR [34–36], and high resolution melting curve (HRM) analysis [37–39].
2. Screening laboratory tests for β-thalassemia and HbE carriers
Two laboratory tests are usually performed for screening of the β-thalassemia 
carriers: automated red cell indices (mean corpuscular volume; MCV, mean cor-
puscular hemoglobin; MCH, and red cell distribution width; RDW) and one-tube 
osmotic fragility test (OFT). The screening tests for HbE carrier comprise those 
performed for the β-thalassemia screen plus the tests used for HbE screen. These 
tests include dichlorophenolindophenol precipitation (DCIP) test [40], HbE-tube 
test [15], and hemoglobin E test [16]. The results of these screening tests indicate 
chance that the blood samples are carriers of either β-thalassemia or HbE.
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2.1 Red blood cell indices
Red blood cells or erythrocyte indices used for screening for β-thalassemia carri-
ers and HbE carriers conventionally included mean corpuscular volume (MCV) and 
mean corpuscular hemoglobin (MCH). These red cell indices must be obtained by 
automated blood cell analyzers. Normal ranges of MCV and MCH are 85.5 ± 6.8 fL 
and 27.1 ± 3.1 pg, respectively. Cut-off points of MCV and MCH are 80 fL and 27 pg, 
respectively.
MCV and MCH in β-thalassemia carriers are 68.7 ± 5.4 fL and 20.6 ± 2.1 pg. In 
HbE carriers, MCV and MCH values are 76.3 ± 4.6 fL and 24.2 ± 1.5 pg [41]. We 
found that the MCV and MCH in normal individuals, β-thalassemia carriers, and 
HbE carriers were significantly different [41]. With the cut-off points of 80 fL, 
MCV has been shown to be effective in screening for the β-thalassemia carriers 
with sensitivity and specificity of 92.9 and 83.9%, respectively [42, 43]. At 26.5 pg 
cut-off point of MCH, Pranpanus and co-workers found 92.5% sensitivity and 
83.2% specificity of MCH in screening for the β-thalassemia carriers. At the cut-off 
point of 80 fL for MCV and 27 pg for MCH, Karimi and co-workers found 98.5% 
sensitivity of MCH, which was more than that of MCV (97.6% sensitivity) in 
screening for β-thalassemia carriers. They concluded that the MCH was better than 
MCH [44].
MCV and MCH are not effective in screening for HbE carriers since mean 
levels in HbE carriers are just slightly lower than those in normal individu-
als, but the distribution overlaps substantially. Yeo et al. showed that the use 
of 80 fL cut-off point could miss cases of HbE carriers [45]. Ittarat et al. 
showed that 5% of HbE carriers would be missed in 80-fL cut-off points of 
MCV was used [46]. This group suggested the use of some discriminant func-
tions, F1 = 0.01 × MCH × (MCV) or F2 = RDW × MCH × 2(MCV)/Hb × 100 or 
F3 = MCV/RBC, to increase effectiveness of using red cell indices for screening 
for HbE carriers. Our unpublished data showed that using 80-fL and 27 pg cut-off 
points of MCV and MCH, respectively, did not miss cases HbE carriers regardless 
of hemoglobin levels (4.2–15.1 g/dL).
2.2 One-tube osmotic fragility test (OFT)
This simple test utilizes osmosis, the movement of water from lower to higher 
salt concentration region, to test for the osmotic resistance of the red blood cells. In 
a hypotonic condition, the fixed concentration of salt on the outside is lower than 
that on the inside of red blood cell, resulting in net water movement into the red 
blood cell. Normal red blood cells are then lysed and the mixture then turns red-
dish and clear. Red blood cells of the β-thalassemia and HbE carriers have higher 
osmotic resistance and thus have slower rupture rate, and the mixture remains 
turbid. Different laboratories may be using slightly different recipes for preparation 
of hypotonic salt solution such as 0.36% NaCl in distilled water (DW), 0.36% NaCl 
in phosphate buffer or buffered saline solution (BSS), and 0.45% NaCl in glycerine 
or glycerine saline solution (GSS). All of these solutions are normally based on the 
same concept of kinetic osmotic fragility.
2.2.1 0.36% NaCl-based and BSS-based one-tube osmotic fragility test
By mixing the 20 μL of red blood cells of normal and β-thalassemia carriers in 
2 mL of 0.36% NaCl in DW (0.36 g NaCl dissolved in 100 mL DW) or BSS (0.32 g 
NaCl, 0.05 g Na2HPO4, 0.01 g NaH2PO4 dissolved in 100 mL DW) and leave 
for 5 min, the normal red blood cells will completely lyse and the mixture turns 
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reddish-clear and reported as OFT-Negative. In contrast, the mixture of blood 
samples of β-thalassemia carriers and 0.36% NaCl remains turbid at 5 min and 
reported as OFT-Positive. In case that the appearance of the mixture is between 
positive and negative OFT-results, it is reported as OFT-suspicious (Figure 1). 
Chow et al. showed that this test has 95% sensitivity and 86% specificity for screen-
ing the β-thalassemia carrier [47]. Bobhate et al. demonstrated 97.1% sensitivity 
and 100% specificity of this test, which they called NESTROFT, in screening for 
β-thalassemia carriers [48], while Mamtani et al. showed 93.4% and 97.2% sensi-
tivity and specificity of this test for screening of the β-thalassemia carriers [49]. 
For HbE carriers, Fucharoen et al. showed 37.7% false negative OFT result in HbE 
carriers [50], which was closed to our unpublished data that showed approximately 
29.4% false negative results.
2.2.2  0.45% NaCl in glycerine or glycerine saline solution (GSS)-based one-tube 
osmotic fragility test
This test was established by Prof. Dr. Torpong Sa-nguansermsri of Thalassemia 
Unit, Department of Pediatrics, Faculty of Medicine, Chiang Mai University and 
named this test “Erythrocyte Osmotic Fragility Test” (EOFT) [51]. In this platform, 
the influx of water into the erythrocyte is slow and hemolysis can be measured at 
any points of time after mixing blood with 0.45% GSS [1.424 g Na2HPO4.2H2O, 
0.262 g NaH2PO4.2H2O, 2.812 g NaCl, 19.27 g glycerine (87%), and DW to make 
1000 mL]. Technically, 10 μL of EDTA blood is mixed with 10 mL of 0.45% GSS 
and read 620-nm absorbance at 15, 30, 45, 60, and 120 s, before calculating hemoly-
sis rate at every time point.
The cut-off point of hemolysis rate is 60%. Positive blood samples have hemo-
lysis rate <60%, while the blood samples having hemolysis rate ≥60% is judged as 
negative. The β-thalassemia carriers have hemolysis rate of 17.6 ± 8.1%. Hemolysis 
rate of 32.6 ± 13.2% is observed in HbE carriers [52, 53].
2.2.3  0.45% NaCl in glycerine or glycerine saline solution (GSS)-based one-tube 
osmotic fragility test expressed in “hemolysis area”
The portable spectrophotometer was invented and capable of reading absor-
bance and transmission of red light through the red blood cell suspension inside 
Figure 1. 
0.36% NaCl-based and BSS-based one-tube osmotic fragility test for screening of β-thalassemia and HbE 
carriers. The β-thalassemia carriers all have the positive OFT results, while HbE carriers have either positive, 
negative, and suspicious OFT results (see the text for detail).
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cuvette [54]. To perform this test, 20 μL of EDTA blood is mixed with 5 mL of 
GSS in 12 × 75 polypropylene cuvette. Then place the cuvette inside the cuvette 
holder of the portable spectrophotometer (red dots in Figure 2(A)) and start the 
machine. Light transmission (red line in Figure 2(B)), light absorbance (black line 
in Figure 2(B)), and HemeArea or hemolysis area (green line in Figure 2(B)) are 
generated simultaneously in real-time manner. At 120 s, the numeric HemeArea 
(or hemolysis area) is shown in green alphabets (Figure 2(B)).
Cut-off point of the hemolysis area is 52.4 unit. Blood samples having the hemo-
lysis area less than these cut-off values are judged as “positive samples,” while those 
samples having the hemolysis area ≥ 52.4 units are classified as “negative sample.” 
The hemolysis area of normal individuals was 67.1 ± 12.6 units. In contrast, the 
hemolysis area of HbE carriers, β-thalassemia carriers were found to be 36.4 ± 13.9, 
18.6 ± 1.1, respectively [54].
2.3 Dichlorophenolindophenol precipitation (DCIP) test
In dichlorophenolindophenol precipitation (DCIP) test, 2,6-dichiorophenol 
indophenol (DCIP) were oxidizing chemicals and used as indicator of ascorbic 
acid measurement. Hemoglobin E is resulted from amino acid change at codon 
26 of β-globin chain from glutamic acid to lysine. This change makes contact of 
α-globin chain and βE-globin chain less stable. Thus, in DCIP solution, molecule of 
HbE changes from tetramer to monomer, freeing sulfhydryl group of amino acid, 
oxidized by the DCIP, denatured, and precipitated [55].
The 500-mL DCIP reagent is composed of 4.36 g Trizma base, 2.68 g EDTA-
Na2.2H2O, 0.0276 g of DCIP, and 0.05 g of saponin. The pH of reagent is adjusted 
to 7.5 by using 6 N HCl. To perform test, 20 μL of EDTA blood is mixed with 5 mL 
DCIP reagent. The mixture is incubated in 37°C-water bath for 1 h before precipita-
tion occurs in case of HbE carriers. To enhance visualization, 20 μL of 6% (w/v) 
ascorbic acid is dropped into the mixture and the color of mixture turns from deep 
blue to pale red (Figure 3).
This test is now commercially available in Thailand. The commercial DCIP 
reagent has the same ingredient and incubation condition as the original test, 
except the volume of reagent is scaled down to 2 mL. The examples of commercially 
DCIP reagent presently distributed in Thailand are THALCON™ and KKU-DCIP™ 
reagent (Figure 4).
Figure 2. 
Portable spectrophotometer (A) and on-screen GSS-based OFT result with the hemolysis area (HemeArea in 
the screen) shown in the screen (B).
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This test has been validated and shown to be effective in screening for HbE car-
riers. Analysis in the author’s laboratory showed that this test had 100% sensitivity 
and 98.4% specificity in screening for HbE carriers [56]. Wiwanitkit et al. found 
almost the same effectiveness of this test in HbE screen; 100% sensitivity and 97.2% 
specificity [14]. Chapple et al. re-evaluated the KKU-DCIP reagent kit and found 
100% sensitivity and 92% specificity for screening for HbE carriers [55].
2.4 HbE-tube test
This test was invented by the author in 2012 [15]. It is based on the principle of 
anion-exchange liquid chromatography. The diethyl aminoethyl (DEAE)-cellulose 
having positive charge in buffer having fixed amount of NaCl is placed in the 
test tube. This condition allows all hemoglobins to bind DEAE-cellulose, except 
HbE and HbA2. Then these two hemoglobins will still dissolve in the supernatant. 
However, since HbE quantity is more than 10% in HbE carriers, then in case of 
HbE carrier, the supernatant color is red. In contrast, in non HbE, that is, no HbE 
in blood, the supernatant is colorless (Figure 5). This test is simple, requiring no 
incubation and centrifugation. Standing the test tube after mixing the blood for 
about 10 min is enough for visualizing the supernatant color.
Figure 4. 
DCIP test results obtained by commercial DCIP kit. The black lines placed behind the tube aid the result 
reading. If we cannot see the black lines, the result is positive. If the black lines are clearly seen, the result is 
negative. DCIP test produces turbid solution.
Figure 3. 
Dichlorophenolindophenol precipitation (DCIP) test. The DCIP results before adding ascorbic acid have 
deeply blue color, but after ascorbic acid addition, the color turns to pale red. The amount of precipitation is 
increased in homozygous HbE (EE), compared to HbE carrier (AE). No precipitation is seen for non-HbE 
(A2A). Modified from Ref. [53].
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To perform the test, 15 μL packed red cell (PRC) is added to pre-prepared 
DEAE-cellulose suspension in the transparent test tube (0.5 mL DEAE-cellulose 
suspension in 1.0 mL glycine-NaCl buffer containing 0.2 M glycine–0.01% KCN–
7.5 mM NaCl). The tube is shaken briefly, left for 5 min at room temperature, and 
spun at 3500 round per minute for 5 min before reading the results by visualizing 
the color of supernatant as shown in Figure 5.
This test was simple and effective in screening of HbE carriers. Its sensitiv-
ity and specificity for HbE screen are 100%. The reagent can be kept in the cold 
(2–8°C) for 5 months [15].
2.5 HbE screen test
This test was initially invented by Prof. Dr. Torpong Sa-nguansermsri of The 
Thalassemia Unit, Department of Pediatrics, Faculty of Medicine, Chiang Mai 
University, Thailand [57] and adopted for HbE screen in pregnant women by 
Sirichotiyakul et al. [58]. This test was also established in author’s laboratory 
(Unpublished data). This test works under the principle of anion-exchange column 
chromatography, modified from microcolumn chromatography for HbA2 quantifi-
cation [59, 60].
The test comprises small syringe packed inside with anion-coated resin such 
as diethylaminoethyl (DEAE)-Sephadex A50 suspended in Tris-HCl-KCN (THK) 
buffer (6.057 g tris hydroxymethyl aminomethane, 0.1 g KCN, 4 N HCl to adjust 
pH), pH 8.5. On passing hemolysate through this microcolumn, all hemoglobins 
bind to the resin. However, passing the eluting buffer (THK buffer, pH 8.2), only 
HbE and HbA2 are eluted. If the patients have HbE, the color of entire length of the 
microcolumn will be red. If the patients do not have HbE, the color of this point will 
be colorless (Figure 6).
To perform this test invented by Prof. Dr. Torpong Sanguansermsri, 10 mL hemo-
globin solution (40 μL hemolysate mixed in 5 mL THK buffer pH 8.5) is dropped into 
microcolumn prepacked with DEAE-Sephadex A 50 to the height of 5.0 cm in pasture 
pipette. The solution is allowed to flow through the microcolumn which is subse-
quently equilibrated with 10 mL THK buffer pH 8.5. Finally, HbE and HbA2 are eluted 
out of the microcolumn after poring 10 mL of THK buffer, pH 8.2. At the end, the red 
color of the column is observed. If almost the entire length of microcolumn is red, 
Figure 5. 
HbE tube test for screening of HbE carriers. The positive tube (Pos) is the result of HbE carrier having Hb type 
AE and red supernatant is seen. The negative tube (Neg) is the result of normal individual having Hb type 
A2A and colorless supernatant is seen.
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the result is “Positive.” However, if the red color sticks to only at the top layer of the 
packed resin, the result is “Negative” [57]. This test was evaluated by Sirichotiyakul 
et al. and found to have 100% sensitivity and 100% specificity for HbE screen [58].
Alternatively, the test was modified in author’s laboratory. In this modification, 
DEAE-cellulose was used as the pre-packed resin, and glycine-NaCl buffer was 
equilibrating and eluting buffer. To prepare microcolumn, DEAE-cellulose resin 
suspended in equilibrating buffer (0.2 M glycine + 0.01% KCN) is pre-packed to the 
height of 2.5 cm in 3-mL plastic syringe with 1-cm diameter. To perform the test, 
150 μL hemolysate is dropped into the microcolumn and allowed to pass through 
the resin before eluting HbE with 4 mL eluting buffer (0.2 M glycine + 0.01% 
KCN + 0.005 M NaCl). The red color of the resin packed in column is observed 
in the way resemble that mentioned above (Figure 6). The protocol was named 
“Naked-EyE-Microcolumn-HbE-Screen or NEMES” [61]. This test was found to 
have 100% sensitivity and 100% specificity for screening of HbE carriers.
3. Interpretation of the screening tests
The β-thalassemia carriers always have positive OFT, MCV less than 80 fL, MCH 
less than 27 pg, and negative HbE. In contrast, HbE carriers may have MCV: more or 
less than 80 fL, MCH: more or less than 27 pg, OFT: positive or suspicious or nega-
tive, and hemolysis area: more or less than 52.4 unit. However, all cases of HbE carri-
ers certainly have positive HbE screening tests performed by all mentioned tests.
The MCV, MCH, and OFT are all positive in β-thalassemia diseases such as 
homozygous βO-thalassemia, homozygous β+-thalassemia, compound heterozygous 
βO/β+-thalassemia, compound heterozygous HbE/βO-thalassemia, compound 
heterozygous HbE/β+-thalassemia, and homozygous HbE. However, the DCIP test, 
HbE tube test, and HbE screen test are positive in all cases having HbE in blood.
4. Usefulness of screening tests
In financially burden countries that have considerably high prevalence of thalas-
semia and hemoglobinopathies, initial screen of the carriers in population is essen-
tial. This approach helps to decrease the number of cases seeking further for more 
Figure 6. 
HbE screening test in a modified protocol so-called naked eye microcolumn for HbE screen (NEMES). The AE 
sample shows red color in the resin along entire length of the resin, but not for the A2A sample.
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expensive confirmatory tests. Normally, the sophisticated laboratory tests for conform-
ing the diagnosis of thalassemia and hemoglobinopathies are set up in big centers 
which are mostly located in the city. Thus, selected cases that are screened in for the 
definite diagnosis of thalassemia and hemoglobinopathies have to travel a long distance 
to the city. This would not consume much money for traveling and for laboratory tests.
4.1 Confirmatory method for thalassemia and hemoglobinopathies
Aims of confirmatory tests are to make the definite diagnosis of β-thalassemia 
and HbE. These tests generally performed only in blood samples having positive 
results of screening tests. Two sets of confirmatory tests are generally performed; 
hemoglobin studies and DNA analysis.
4.1.1  Hemoglobin studies by cellulose acetate electrophoresis (CAE) at alkaline 
condition
This test separates hemoglobins in blood by their negatively molecular net 
charge. Hemoglobins are allowed to dissolve in Tris-EDTA-Borate (TBE) buffer 
pH 8.6. This pH is more than isoelectric points (pI) of all hemoglobins (approxi-
mately 6.5–7.5) [62, 63]. At this pH, all hemoglobins have negative charge and 
migrate from cathodic part toward anodic end of the electrophoretic chamber.
In 1 L of TBE buffer, it is composed of 12.0 g tris-hydroxymethyl aminomethane 
(Tris), 1.22 g ethylenediaminetetraacetic acid (EDTA), and 1.5 g boric acid.
The electrophoresis is performed at a constant voltage of 250–300 volts for 
15–20 minutes or until HbA and HbE bands are clearly separated. At the end of 
electrophoresis, the hemoglobin bands on cellulose acetate plate are stained for 
5 minutes with Ponceau S stain (2 g of Ponceau S powder, 30 g of trichloroacetic 
acid, and 30 g of sulfosalicylic acid in 1 L of distilled water) and destained for 
5 minutes in destaining solution (5% acetic acid in distilled water). Finally, the 
cellulose acetate plate is made clear for permanent record by immersing for 5 min-
utes in clearing solution (4 volume of methanol +1 volume of glacial acetic acid) 
and dried by using hair dryer. Hemoglobin pattern from cathodic to anodic ends is 
Constant Spring-A2/E/C/O-S/D/Lepore/G-F-A-Portland-Bart’s-H [64] (Figure 7). 
Hemoglobin patterns on CAE at alkaline condition are shown in Table 1. In the past, 
densitometer was used to determine quantities of hemoglobins in blood samples. 
However, this technique is not conventionally performed presently because it may 
give falsely high levels of hemoglobins if the background is not completely cleared. 
However, CAE results can still give types of hemoglobins in blood samples. Thus, by 
Figure 7. 
(A) Hemoglobin patterns on cellulose acetate electrophoresis (CAE) at pH 8.6. (B) Example of hemoglobin 
pattern on CAE at pH 8.6 stained with Ponceau S stain.
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using this technique, further tests must be done in order to determine the level of 
HbA2 and HbF. Raised level of HbA2 beyond normal range is the diagnostic marker 
for β-thalassemia carriers, while elevated level of HbF helps identify the high HbF 
condition found in the hereditary persistence of fetal hemoglobin (HPFH).
4.1.2 Hemoglobin study by microcolumn chromatography
This test is preliminarily aimed to quantify HbA2 levels that help diagnosis of 
the β-thalassemia carrier. However, HbE has the same pI as HbA2, thus these two 
hemoglobins are co-eluted. Microcolumn chromatography is an anion-exchange 
chromatography-based method. Anion-resin such as DEAE-cellulose or DEAE-
Sephadex A50 suspended in appropriate buffer is packed in the microcolumn. On 
passing hemolysate through the packed resin, negatively charged hemoglobins 
binds to the resin at different binding affinity. HbA2 and HbE bind to the resin at 
the weakest strength (if there is no Hb Constant Spring) and are eluted out easily 
with small amount of external anion such as CL−.
There are two types of microcolumn chromatography, based on the anion-resin 
and buffers used. These include (1) DEAE-Sephadex A50 plus Tris-HCl-KCN buf-
fer, and (2) DEAE-cellulose plus glycine-NaCl buffer.
4.1.2.1 Microcolumn chromatography using DEAE-Sephadex A50 resin
DEAE-Sephadex A 50 resin suspended in Tris-HCl-KCN buffer (0.05 M Tris 
plus 0.1 g KCN/1 L, adjust pH with 4 N HCl) pH 8.5 is packed in pasture pipette to 
the height of 8–9 cm [52]. Then, the microcolumn is applied with 100 μL hemoly-
sate, equilibrated with 10 mL THK buffer pH 8.5. Finally, 10 mL THK buffer pH 8.2 
is applied to the microcolumn to elute HbA2 and/or HbE before 10 mL eluate is 
collected for measuring light absorbance (A) or optical density (OD) at 415 nm. 
This is then called A415-A2 or OD415-A2. For measuring OD415 of total hemoglobin or 
OD415-Total Hb, 100 μL hemolysate is mixed with 10 mL DW before measuring the 
absorbance. The level of HbA2 or HbE is calculated by the Eq. 1 shown below.
  HbA 2 or HbE  (%) =  [ OD 415 −  A 2 / OD 415 − total Hb] × 100 (1)
If percent is less than 10, it is HbA2.
If percent is 10 up, it is HbE.
Normal range of HbA2 by this protocol is 2.62 ± 0.87% [52].
Hb patterns on CAE at pH 8.6 of adult
HbE heterozygote (carriers) EA
HbE homozygote EE (only 1 band of HbE)
βO-thalassemia heterozygote (carriers) A2A
β+-thalassemia heterozygote (carriers) A2A
βO-thalassemia homozygote (βO/βO) A2F
β+-thalassemia homozygote (β+/β+) A2FA
βO/β+-thalassemia (βO/β+) A2FA
HbE/βO-thalassemia (βE/βO) EF
HbE/β+-thalassemia (βE/β+) EFA
Table 1. 
Hemoglobin pattern on CAE at pH 8.6 of β-thalassemia and HbE.
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4.1.2.2 Microcolumn chromatography using DEAE-cellulose
This protocol was described by Wood [64] and modified in the author’s labora-
tory in 2007 [65].
In modified protocol, DEAE-cellulose resin suspended in equilibrating buffer 
(0.2 M glycine + 0.01% KCN) is packed to the height of 2 cm in plastic microcol-
umn with 1.0-cm diameter. Then the microcolumn is applied by 50 μL hemolysate 
(prepared by mixing 1 part of PRC and 6 parts of 0.05% Triton X-100 as hemolysis 
buffer) and flushed with 5 mL eluting buffer (0.2 M glycine +0.01% KCN + 0.005 M 
NaCl). The 5-mL eluate is then collected and measured for absorbance or optical den-
sity at 415 nm (A415-A2 or OD415-A2). OD415 of total hemoglobin is measured in diluted 
hemolysate (50 μL hemolysate mixed with DW to 15 mL) and called OD415-Total.
Calculation of levels of HbA2 or HbE must follow the Eq. 2 shown below.
  HbA 2 or HbE  (%) =  [ OD 415 −  A 2 / OD 415 –total × 3] × 100 (2)
If percent is less than 10, it is HbA2.
If percent is 10 up, it is HbE.
Normal range of HbA2 by this protocol is 1.3–3.7% (mean 2.5%) [64].
For both protocols, if HbA2 level is less than 3.5%, the chance of β-thalassemia 
carrier is excluded. Instead, the cases may be either normal of α-thalassemia carriers. 
However, if HbA2 level is between 3.5 and 10.0%, the case is definitely β-thalassemia 
carrier. In β-thalassemia carriers, mean HbA2 is 4.8% with the range 3.7–7.0% [64].
4.1.2.3 Hemoglobin study by alkaline denaturation test of Betke
This test works under the principle that HbF is resistant to alkaline treatment, 
while other hemoglobins are not [66]. Therefore, if hemoglobin solution of normal 
adult is mixed with alkaline solution, HbA, HbA2 is denatured, leaving only HbF 
dissolved in the solution. The dissolved HbF can be determined for its level by 
measuring optical density at 540 nm.
The reagents that are required for this test comprise Drabkin’s solution (0.20 g 
of K3Fe(CN)6, 0.05 g of KCN, DW to 1 L), 1.2 N NaOH, and saturated ammonium 
sulphate.
To perform the test, 200 μL hemolysate is mixed in 3.8 mL of Drabkin’s solution 
to prepare cyanmethemoglobin. Thereafter, 2.8 mL of cyanmethemoglobin solution 
is mixed with 200 μL of 1.2 N NaCl and shaked vigorously for 2 min exactly before 
adding 2.0 mL of saturated ammonium sulphate. Then, the precipitated hemoglo-
bins are filtered out, and the OD540 of filtrate is measured and named OD540-filtrate. 
OD540 of total hemoglobin is measured in a mixture of 400 μL of hemolysate and 
6.75 mL of Drabkin’s solution and named OD540-Total.
The percentage of HbF is calculated by the following Eq. 3:
  HbF or Alk F  (%) =  ( OD 540 − filtrate / OD 540 − total) × 10 (3)
Since HbF is determined by alkaline treatment, its level is then named Alkaline F 
or, simply, Alk F. Besides HbF, Hb Bart’s (γ4) is also resistant to alkaline treatment. This 
protocol has maximum detection limit at only 50% of HbF. If the alkaline denaturation 
test is performed in fetal blood sample, the Alk F will not be more than 50%. Therefore, 
other techniques such as HPLC, CZE should be used to measure HbF in fetal blood.
Alk F is not diagnostic marker for both β-thalassemia carriers and HbE car-
riers. However, increased HbF level presently is considered advantageous in 
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β-thalassemia and β-hemoglobinopathies [6]. Patients with β-thalassemia disease 
who also inherit high HbF gene or quantitative trait loci (QTLs) will have mild 
clinical symptoms. Parents having high HbF gene can pass this gene to their 
β-thalassemia offspring. Thus, determining HbF in parents is useful in this way.
4.1.2.4  Hemoglobin study by cation-exchange high performance liquid 
chromatography (HPLC)
Cation-exchange HPLC has become the reference method for typing and quan-
titating hemoglobins in blood samples [19, 67, 68]. In this system, hemoglobins are 
dissolved in buffer having a pH of 6.4 that is less than pI of hemoglobins (6.5–7.5) 
and molecular net charge then is converted to be positive. Different hemoglobins 
then have different amount of positive charge which determines binding strength of 
hemoglobins to negatively charged resin. Hb Bart’s has the weakest binding affinity, 
while Hb Constant Spring has the strongest binding affinity. Therefore, on passing 
external cation, the order of hemoglobins that are eluted fast to slowly should be as 
follows: Hb Bart’s-HbH-HbF-HbAo-HbA2/E-Hb Constant Spring (Figure 8).
Figure 8. 
Hemoglobin pattern of cation-exchange HPLC of normal human adult: A2A. As shown in the figure, major 
hemoglobin is HbAo which accounts for 82.4%, while the minor HbA2 accounts for 2.6%. Other minor hemoglobins 
are labeled P2 and P3, which are Hbs A1a, A1b, and A1c mixture. HbF peak is negligible and reported as 0.0%. 
This HPLC result may be that of normal individuals or α-thalassemia carriers. It is noted that this kind of cation-
exchange HPLC pattern may be also observed in carriers of α-thalassemia 1 and carriers of α-thalassemia 2.
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HbA is normally derivatized to several fractions including the minor Hbs A1a, 
A1b, A1c, and major HbAo. The minor Hbs A1a, A1b, and A1c are eluted just after 
HbF. For routine Hb typing work, only the major HbAo is usually reported to clini-
cians. This makes sum of hemoglobin peaks does not equal to 100%.
HbE, which is common in Southeastern part of the world, is co-eluted with 
HbA2. However, most of the manufacturers design program to read hemoglobin 
peak at the A2 region as only HbA2. Therefore, the operator must be aware that if 
the percentage of A2-peak is more than 10, it is HbE plus HbA2 and indicates that 
the sample has HbE. The operator must report HbE or HbE plus HbA2, instead of 
reporting HbA2 as reported by the machine.
There are several manufacturers producing the HPLC machine in the world 
and the operating procedures as well as quality control protocols are established 
specifically for each brand. Most importantly, all of these brands generate identical 
separation peaks of hemoglobins. Figure 8 shows example of hemoglobin pattern 
obtained from Variant™ Hemoglobin Analysis System, the widely used HPLC 
machine in Thailand. In this protocol, the hemoglobin types in normal human 
adults are A2A with HbA2 of 2.6 ± 0.38% [19].
Contrast to the CAE at pH 8.6, hemoglobins separated by the cation-exchange 
HPLC are automatically calculated for their proportions in blood. Therefore, 
both types and quantities of hemoglobins are usually obtained when run in this 
platform.
Figure 9. 
Hemoglobin pattern of cation-exchange HPLC of β-thalassemia carrier in human adult: A2A. As shown in the 
figure, major hemoglobin is HbAo which accounts for 78.6%, while the minor HbA2 accounts for 5.9%. Other 
minor hemoglobins are labeled P2 and P3, which are Hbs A1a, A1b, and A1c mixture. HbF peak is negligible 
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4.2  Cation-exchange HPLC hemoglobin patterns of β-thalassemia carriers and 
HbE carriers in human adults
Hemoglobin patterns obtained from the cation-exchange HPLC of β-thalassemia 
and HbE are totally different. In carrier state, β-thalassemia carriers in adult life 
have normal Hb types for adult which is A2A, but HbA2 levels is increased to the 
levels of 5.9 ± 1.35% (Figure 9) [19]. HbE carriers in adult life have abnormal Hb 
typing by the cation-exchange HPLC which is AE with HbE (plus A2) of 27 ± 3.93% 
[19], as shown in Figure 10.
4.3  Cation-exchange HPLC hemoglobin patterns of β-thalassemia diseases and 
HbE disease in human adults
Hemoglobin patterns by the cation-exchange HPLC of adult β-thalassemia 
disease consist of several patterns depending on the combination of the abnormal 
β-thalassemia mutations.
4.3.1 Homozygous βO-thalassemia
Individuals of homozygous βO-thalassemia (βO/βO) are usually affected by the 
severe thalassemia disease and require regular blood transfusion. This group of patients 
Figure 10. 
Hemoglobin pattern of cation-exchange HPLC of HbE carrier in human adults: EA. As shown in the figure, 
major hemoglobin is HbAo which accounts for 59.2%, while the minor HbE (plus A2) accounts for 24.9%. 
Other minor hemoglobins are labeled P2 and P3, which are Hbs A1a, A1b, and A1c mixture. HbF peak is 
negligible and reported as 0.0%.
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is previously classified as thalassemia major, but now as transfusion dependent thalas-
semia [69]. Hence, hemoglobin patterns of homozygous βO-thalassemia in adult life of 
human should consist of HbF and HbA2 with no HbA prior to blood transfusion, that 
is, A2F (Figure 11). However, after recent blood transfusion, the hemoglobin types of 
A2FA are shown. HbA is certainly from the transfused blood ( Figure 12).
4.3.2 Homozygous β+-thalassemia
Individuals of homozygous β+-thalassemia always have mild clinical symptoms 
and previously are classified as β-thalassemia intermedia. The β-thalassemia 
intermedia cases usually require no blood transfusion. Thus, now this group of 
patients is newly classified as non-transfusion dependent thalassemia (NTDT) 
[69]. Hemoglobin pattern on cation-exchange HPLC of homozygous β+-thalassemia 
is quite resembling to that of transfused homozygous βO-thalassemia, that is, 
A2FA. However, single population of red blood cells on blood smear is also revealed 
in this homozygous β+-thalassemia, in contrast for dimorphic population in case of 
transfused homozygous βO-thalassemia. Figure 12 shows hemoglobin pattern by 
cation-exchange HPLC of the homozygous β+-thalassemia.
Figure 11. 
Cation-exchange HPLC pattern of homozygous βO-thalassemia prior to blood transfusion, which is read as 
A2F (F: 97.8%, A2: 2.2%) (credit to Eaktong Limveeraprajak of Sawan Pracharak Hospital).
Figure 12. 
Cation-exchange HPLC hemoglobin pattern A2FA seen in homozygous β
+-thalassemia and compound 
heterozygous β+/βO-thalassemia (HbAo: 24.6%, HbF: 68.5%, HbA2: 3.9%).
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4.3.3 Compound heterozygous βO/β+-thalassemia
Patients with compound heterozygous βO/β+-thalassemia always have 
severe disease and may require blood transfusion. Thus, they are classified as 
TDT. Hemoglobin patterns by cation-exchange HPLC of transfused and non-
transfused cases is A2FA, being similar to homozygous β
+-thalassemia (Figure 12). 
However, the compound heterozygous βO/β+-thalassemia has thalassemic red 
blood cell morphology like homozygous βO-thalassemia. In contrast, red blood cell 
morphology of homozygous β+-thalassemia is less abnormal than the other two 
β-thalassemia mentioned above.
Hb patterns by the cation-exchange HPLC of adult HbE disease also comprise 
several varieties depending on combination of βE mutation.
4.3.4 Homozygous HbE
Homozygous HbE (βE/βE) is the mild form of β-thalassemia disease. The 
patients usually have good clinical symptom with only mild anemia with no need 
of blood transfusion. Thus, cation-exchange HPLC always shows HbE as major 
hemoglobin and HbF as the minor hemoglobin; that is, EF (Figure 13). Sometime, 
this hemoglobin type of EF may be confused with that of HbE/βO-thalassemia 
as HbF in some cases of the later condition may be as low as 4.5% [70] and 2.1% 
[19]. This low level of HbF may overlap with that seen in homozygous HbE 
(4.3 ± 2.66%) [19]. Again, red blood cell morphology will help identify if the case 
is homozygous HbE or the HbE/βO-thalassemia. Red blood cell morphology on 
Figure 13. 
Hemoglobin pattern by cation-exchange HPLC of homozygous HbE in adults. The major peak contains HbE 
plus HbA2, but it is labeled A2 by software. Thus, level of HbE plus HbA2 in this case is 77.3, and that of HbF is 
1.7%. This case has no HbA, but the software mislabeled the HbA1 fraction as Ao.
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blood smear stained with Wright-Giemsa stain is totally different between homo-
zygous HbE and HbE/βO-thalassemia. In homozygous HbE, mild change of red 
blood cell morphology with considerable amount of target cells is usually observed. 
In contrast, thalassemia type of red blood cell morphology is typical for the HbE/
βO-thalassemia.
4.3.5 Compound heterozygous βE and βO-thalassemia
Individuals with compound heterozygote of βE and βO-thalassemia are always 
affected by the thalassemia disease and some require blood transfusion. Therefore, 
the hemoglobin patterns by cation-exchange HPLC of this case will be EF 
(61.2 ± 13.6% HbE, 31.1 ± 14.5% HbF) prior to blood transfusion [19] and EFA after 
recent blood transfusion (Figure 14).
4.3.6 Compound heterozygous βE and β+-thalassemia
Individuals with compound heterozygote of βE and β+-thalassemia have mild 
clinical symptoms and classified as NTDT. Therefore, interference of transfused 
blood is not possible. The cation-exchange HPLC pattern of hemoglobin in this case 
should be EFA. This is because some β-globin chains are still produced.
4.3.7 Double form of HbE carrier and HbH disease
This thalassemia syndrome is conventionally termed AEBart’s disease. This is 
a mild form of α-thalassemia syndrome, and blood transfusion is not required. 
Thus, transfused blood would not also interfere result reading in this situation. 
Hemoglobins A, E (with A2), Bart’s are always seen under the cation-exchange 
HPLC (Figure 15). This is why it is called AEBart’s disease.
4.3.8 Double form of HbE homozygote and HbH disease
This is also a mild form of α-thalassemia disease that shows hemoglobins E, 
F, and Bart’s in the cation-exchange HPLC. It is thus called EFBart’s disease. By 
running the cation-exchange HPLC, Hbs E, F, and Bart’s are always seen in the 
 chromatogram.
Figure 14. 
Hemoglobin pattern in cation-exchange HPLC of cases with HbE/βO-thalassemia (F 53.1%, E 35.8%).
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4.3.9 Double form of HbE/βO-thalassemia and HbH disease
This is a rare form of thalassemia syndrome. On running in the cation-exchange 
HPLC, EFBart’s pattern of hemoglobin is also seen, being similar to the double form 
of homozygous HbE and HbH disease. Red blood cell morphology on blood smear 
may help differentiate these two conditions, but skillful personnels are needed to 
examine red blood cell morphology. However, DNA analysis in the only technique 
that can correctly differentiate this EFBart’s syndrome.
5. Hemoglobin study by capillary zone electrophoresis (CZE)
Capillary zone electrophoresis (CZE) has been introduced for use as a tool for 
analysis of hemoglobin variants [23–27, 71]. Conventionally, separation of hemo-
globin is performed in alkaline condition, in which HbH has the maximum molecu-
lar negative charge, followed, respectively, by Hb Bart’s, HbA, HbF, HbsA2/E, 
and Hb Constant Spring. The separation is based on high voltage (7500 V) and 
electro-endo-osmotic force (EOF). Hemoglobins are forced in the system to move 
from anode to cathode with the cuvette placed at the cathodic end. Once hemoglo-
bin band moves into the cuvette, the 415-nm absorbance is measured and the light 
signals are converted by the software to electropherogram. Each hemoglobin has 
its own location or zone in the electropherogram, HbCS-zone 2: Z(C), HbA2-zone 
3: Z(A2), HbE-zone 4: Z(E), HbF-zone 7: Z(F), HbA-zone 9: Z (A), Hb Bart’s – 
zone 12, and Hb H – zone 15. HbE and HbA2 are clearly separated by this system 
(Figures 16 and 17).
5.1 The CZE pattern of β-thalassemia carriers and HbE carriers
In β-thalassemia carrier at adult life, the CZE pattern of hemoglobin is similar to 
that obtained from cation-exchange HPLC. The normal hemoglobin typing result 
of A2A or A2FA with HbA2 levels of more than 3.5% (5.4 ± 0.5%) and HbF levels of 
less than 2% (0.9 ± 1.4%) are always observed [27] (Figure 18).
In HbE carrier of adult life, the hemoglobin pattern of CZE is different from 
that of cation-exchange HPLC. HbE and HbA2 co-eluted in the cation-exchange 
HPLC. In CZE, HbE moves behind HbA2. Thus, hemoglobin pattern of HbE carrier 
Figure 15. 
Cation-exchange HPLC of hemoglobin component in AEBart’s disease. HbE: 13.5%, HbA0: 71.8%, Hb Bart’s 
(no numeric proportion as the analysis software was not designed for Hb Bart’s quantification).
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in CZE should be A2EFA. The percentage of these hemoglobins is as follows: HbA2: 
3.5 ± 0.4%, HbE: 25.6 ± 1.4%, and HbF: 0.4 ± 0.8% [27]. HbE level in the CZE sys-
tem is usually lower than that obtained from cation-exchange HPLC (27.8 ± 7.5%). 
This is due to the fact that the level of HbE from HPLC is the sum of HbE and HbA2 
that are co-eluted, while only HbE is reported in the CZE system. Thus, performers 
must be careful in reporting HbE. HbA2 level is slightly elevated. This confirms that 
HbE carrier also acts as mild β-thalassemia carrier (Figure 19).
5.2 The CZE pattern in β-thalassemia disease and HbE disease
CZE pattern of hemoglobins in β-thalassemia disease in adults depends on types of 
the disease. Although, principles of separation are different, the patterns of hemoglobin 
Figure 16. 
CZE electropherogram of normal human hemoglobins. HbA: 94.3%, HbF: 2.4%, HbA2: 3.3%.
Figure 17. 
CZE pattern of hemoglobins from zone (Z) 1 to zone (Z) 15.
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Figure 19. 
CZE pattern of hemoglobin of HbE carrier.
Figure 18. 
CZE pattern of hemoglobins of β-thalassemia carrier.
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in β-thalassemia disease and HbE disease obtained from CZE are quite similar to those 
obtained from cation-exchange HPLC. For homozygous βO-thalassemia, A2F is the 
typical hemoglobin typing results. For homozygous β+-thalassemia and compound 
heterozygous β+/βO-thalassemia, the A2FA is generally seen in CZE platform.
CZE patterns of hemoglobins in HbE disease in adults also depend on types of 
the diseases. However, as HbE and HbA2 are clearly separated in the CZE platform, 
these two hemoglobins must be separately reported. For example, in HbE/βO-
thalassemia, for example, A2EF must be reported together with the proportion of 
each hemoglobin (Figure 20).
6. Hemoglobin study by monoclonal antibody
Thalassemia and hemoglobinopathies can be identified accurately by using 
monoclonal antibodies (mAbs) against human hemoglobins [72, 73]. Application 
of mAb-based protocols aims primarily to identify the carriers of thalassemia and 
hemoglobinopathies. For instance, α-thalassemia carrier can be detected by using 
mAbs against Hb Bart’s [29] and HbH [74]. Immunochromatographic strip test 
utilizing mAb to Hb Bart’s was produced and successfully applied for screening 
α-thalassemia carriers [32, 75].
Figure 20. 
CZE pattern of hemoglobins of HbE/βO-thalassemia, composing of A2EF with 4.7% HbA2, 58.9% HbE, and 
36.4% HbF.
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The β-thalassemia carrier can also be identified by using antigen-antibody 
reaction. Since elevated HbA2 level has been shown to be diagnostic marker of the 
β-thalassemia carrier, mAbs against δ-globin chain of HbA2 were produced and 
ELISA set up to quantify HbA2 levels by Shyamala et al. [76]. Using this ELISA, 
Shyamala found mean value of HbA2 in normal and β-thalassemia carrier to be 2.5 
and 5.4%, respectively. The mAb against HbA2 was also produced and sandwich 
ELISA developed in the author’s laboratory [30]. Under this developed sandwich 
ELISA, Kuntaruk found that the levels of HbA2 between normal and β-thalassemia 
carrier were also significantly different (Figure 21). Thus, the β-thalassemia car-
rier can be identified by the sandwich ELISA to quantify HbA2 level.
7. DNA analysis for β-thalassemia and HbE
Analysis of mutations in β-globin gene to identify β-thalassemia and HbE 
is now performed routinely in most laboratories. The finding of the causative 
point mutations in the β-globin gene provides definite diagnosis of these disor-
ders. More than 900 point mutations have been reported for β-thalassemia and 
β-hemoglobinopathies (Globin Gene Server: http://globin.cse.psu.edu/). Certain 
ethic groups have their own pattern of point mutations of β-globin gene [2, 4, 77, 78].
There are several allele-specific PCR protocols for detecting both carrier and 
disease state of β-thalassemia and HbE. These include mutagenically separated 
(MS)-PCR [35] and amplification refractory mutation system (ARMS)-PCR [79]. 
These two protocols were modified and adapted in author’s laboratory. Another 
allele-specific PCR protocol was established in the author’s laboratory and named 
“Multiplex Allele-Specific (MAS)-PCR” [29].
7.1 Identification of β-thalassemia and HbE by MS-PCR
The MS-PCR was used to detect β-globin gene mutations by several centers. 
In author’s laboratory, this PCR protocol was modified and adapted to identify 
Figure 21. 
HbA2 levels determined by sandwich ELISA set up in the author’s laboratory. Note that HbA2 levels in 
β-thalassemia trait are higher than those in normal, HbE trait, homozygous HbE, and suspected α-thalassemia 
trait (modified from [30]).
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the β-globin gene mutations commonly found in Thai individuals. These included 
TTCT deletion or 4 bp-deletion at codons 41/42 (β41/42) and A > T substitution 
at codon 17 (β17) of β-globin gene [80]. These two mutations have been shown to 
account for approximately 67.5% in Thais by author’s survey [29] and 83.9% by 
others’ studies [81]. The MS-PCR was performed in the author’s laboratory under 
the protocol described previously.
7.1.1 MS-PCR for β 41/42 mutation
Procedure: The 25-μL PCR is performed containing 250 ng genomic DNA, 
200 μM of each dNTP; 0.5 units Taq DNA polymerase, 100 ng of “Common 
primer” for β41/42; 5′-TCA TTC GTC TGT CCA TTC TAA AC-3′, 150 ng of “Normal 
primer” for β41/42; 5′-TTC CCA CCA TTA GGC TGC TGG TGG TCT ACC CTT GGA 
CCC AGA GGT TCT T-3′, 250 ng of “Mutant primer” for β41/42; 5′-ACC CTT GGA 
CCC AGA GGT TGA G-3′, 10 mM Tris pH 8.8; 50 mM KCl and 1.5 mM of MgCl2.
Thermal cycles: A total of 35 thermal cycles was carried out with each cycle 
comprising DNA denaturation at 94°C for 1 min, primer annealing at 56°C for 
1 min, and primer extension at 72°C for 1 min; the initial denaturation was 
extended to 4 min while the final extension was prolonged to 5 min.
Detection of amplified products: The amplified products were separated in 
2.5% agarose gel electrophoresis at 120 V for 15–20 min before visualizing with a 
UV-transilluminator. The fragments sizing 324 and 351 bp indicate presence and 
absence of the β41/42 mutation, respectively (Figure 22).
Interpretation: Samples having only 324-bp amplified fragments are homozy-
gote for β41/42 with genotype β41/42/β41/42. Samples having only 351-bp fragments are 
negative for the β41/42 with genotype βA/βA or βT/βT (A represents HbA; T represents 
other types of β-globin gene mutation). Samples having both 324 and 351-bp 
amplified products are heterozygote for the β41/42 with genotype of either β41/42/βA or 
β41/42/βT (A represents HbA; T represents other types of β-globin gene mutation).
7.1.2 MS-PCR for β17 mutation
Procedure: The 25-μL PCR is performed containing 250 ng genomic DNA, 
200 μM of each dNTP; 0.5 units Taq DNA polymerase, 100 ng of “Common 
primer” for β17; 5′-GGC AGA GAG AGT CAG TGC CTA-3′, 150 ng of “Normal 
Figure 22. 
MS-PCR for detecting β41/42 mutation. Lanes 1 and 3 are negative for the β41/42 mutations as only 351-bp 
amplified products are seen. Lanes 2, 4, and 5 are heterozygote for the β41/42 mutation as both 3510 and 324-bp 
amplified products are seen.
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primer” for β17; 5′-ACC TGA CTC CTG AGG AGA AGA CTG CCG TTA CTG CCC 
TGT GGG ACA-3′, 100 ng of “Mutant primer” for β17; 5′-TCT GCC GTT ACT GCC 
CTG TGG CAC-3′, 10 mM Tris pH 8.8; 50 mM KCl and 1.5 mM of MgCl2.
Thermal cycles: A total of 35 thermal cycles was carried out with each cycle 
comprising DNA denaturation at 94°C for 1 min, primer annealing at 59°C for 
1 min, and primer extension at 72°C for 1 min; the initial denaturation was 
extended to 4 min while the final extension was prolonged to 5 min.
Detection of amplified products: The amplified products were separated in 
2.5% agarose gel electrophoresis at 120 V for 15–20 min before visualizing with a 
UV-transilluminator. The fragments sizing 170 and 190 bp indicate presence and 
absence of the β17 mutation, respectively (Figure 23).
Interpretation: Samples having only 170-bp amplified fragments are homozy-
gote for β17 with genotype β17/β17. Samples having only 190-bp fragments are nega-
tive for the β17 with genotype βA/βA or βT/βT (A represents HbA; T represents other 
types of β-globin gene mutation). Samples having both 170 and 190-bp amplified 
products are heterozygote for the β17 with genotype of either β17/βA or β17/βT (A 
represents HbA; T represents other types of β-globin gene mutation).
7.1.3 MS-PCR for βE mutation or HbE
Procedure: The 25-μL PCR is performed containing 250 ng genomic DNA, 
200 μM of each dNTP; 0.5 units Taq DNA polymerase, 100 ng of “Common primer” 
for βE; 5′-GGC AGA GAG AGT CAG TGC CTA-3′, 100 ng of “Normal primer” for 
βE; 5′-CGT GGA TGA AGT TGG TGG AG-3′, 150 ng of “Mutant primer” for βE; 
5′-CTG CCC TGT GGG CAA GGT GAA CGT GGA TGA AGT TGG TGG AA-3′, 
10 mM Tris pH 8.8; 50 mM KCl and 1.25 mM of MgCl2.
Thermal cycles: A total of 35 thermal cycles was carried out with each cycle 
comprising DNA denaturation at 94°C for 1 min, primer annealing at 56°C for 1 min 
and primer extension at 72°C for 1 min; the initial denaturation was extended to 
4 min while the final extension was prolonged to 5 min.
Detection of amplified products: The amplified products were separated in 
2.5% agarose gel electrophoresis at 120 V for 15–20 min before visualizing with a 
UV-transilluminator. The fragments sizing 160 and 138 bp indicate presence and 
absence of the βE mutation, respectively (Figure 24).
Interpretation: Samples having only 160-bp amplified fragments are homozy-
gote for βE with genotype βE/βE. Samples having only 138-bp fragments are negative 
for the βE with genotype βA/βA or βT/βT (A represents HbA; T represents other types 
Figure 23. 
MS-PCR for identifying β17 mutation. Lanes 4, 5, 6, and 8 are negative for the β17 mutation as only 190-bp 
amplified products are seen. Lanes 7 is homozygote for the β17 mutation as only 170-bp amplified products is seen. 
Lanes 1, 2, and 3 are heterozygote for the β17 mutation since both 170 and 190-bp amplified products are seen.
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of β-globin gene mutation). Samples having both 138 and 160-bp amplified prod-
ucts are heterozygote for the βE with genotype of either βE/βA or βE/βT (A represents 
HbA; T represents other types of β-globin gene mutation).
8. Identification of β-thalassemia and HbE by ARMS-PCR
ARMS-PCR was established by Old et al. [79]. This technique also uses three oli-
gonucleotide primers. However, the length of normal and mutant primers is similar. 
Therefore, size of normal and mutant amplified products is the same and cannot be 
separated in the agarose gel electrophoresis. Thus, two PCRs must be performed in 
the ARMS-PCR. Both PCRs have the same ingredients, except normal and mutant 
oligonucleotide primers are added in separated reaction tubes (M and N-tube). In 
addition, a pair of oligonucleotide primers specific to other gene must also be added 
into both PCRs. The amplified products obtained by this pair of primers are the 
internal control for the ARMS-PCR.
8.1 ARMS-PCR for β41/42
Procedure: Two 25-μL reactions are performed; M-reaction and N-reaction. Both 
M and N-reactions contain 150 ng genomic DNA, 200 μM of each dNTP; 0.6 units 
Taq DNA polymerase, 0.2 μM of “S-primer”; 5′-ACC TCA CCC TGT GGA GCC 
AC-3′, 0.15 μM of “M41/42 primer”; 5′-GAG TGG ACA GAT CCC CAA AGG ACT 
CAA CCT−3′ (for M-reaction only), 0.15 μM of “N41/42 primer”; 5′-GAG TGG ACA 
GAT CCC CAA AGG ACT CAA AGA-3′ (for N-reaction only), 0.2 μM of “P1 primer”; 
5′-GCG ATC TGG GCT CTG TGT TCT-3′, 0.2 μM of “P2 primer”; 5′-GTT CCC TGA 
GCC CCG ACA CG-3′, 10 mM Tris pH 8.8; 50 mM KCl and 1.5 mM of MgCl2.
Thermal cycles: A total of 35 thermal cycles was carried out with each cycle 
comprising DNA denaturation at 95°C for 1 min, primer annealing at 65°C for 1 min 
and primer extension at 72°C for 1 min; the initial denaturation was extended to 
5 min while the final extension was prolonged to 5 min.
Detection of amplified products: The amplified products were separated 
in 2.5% agarose gel electrophoresis at 120 V for 15–20 min before visualizing with 
a UV-transilluminator. The fragments sizing 439 bp is the specific amplified  products, 
and the PCR products sizing 314 bp are the control products (Figure 25).
Figure 24. 
MS-PCR for identifying βE mutation. Lane 1 is negative for the βE mutation as only 138-bp amplified products 
is seen. Lane 2 is heterozygote for βE mutation as both 138-bp and 160-bp amplified products are seen.
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Interpretation: Both M and N-reactions must have the 314-bp control products 
and the results can be read. It both M and N-reactions have 439-bp PCR products, 
the samples are heterozygote for β41/42 with genotype of either β41/42/βA or β41/42/βT (A 
represents HbA; T represents other types of β-globin gene mutation). If the 439-bp 
PCR products are seen in only M-reaction, the samples are homozygote for β41/42 with 
genotype β41/42/β41/42. If samples have the 439-bp PCR products in only N-reaction, 
the samples are negative for the β41/42 with genotypes of either βA/βA or βT/βT (A 
represents HbA; T represents other types of β-globin gene mutation) (Figure 25).
8.2 ARMS-PCR for β17
Procedure: Two 25-μL reactions are performed; M-reaction and N-reaction. 
Both M and N-reactions contain 150 ng genomic DNA, 200 μM of each dNTP; 
0.6 units Taq DNA polymerase, 0.2 μM of “S-primer”; 5′-ACC TCA CCC TGT GGA 
GCC AC-3′, 0.15 μM of “M17 primer”; 5′-CTC ACC ACC AAC TCA GCC ACG 
TTC AGC ATA-3′ (for M-reaction only), 0.15 μM of “N17 primer”; 5′-CTC ACC 
ACC AAC TTC ATC CAC GTT CAC ATT-3′ (for N-reaction only), 0.2 μM of “P1 
primer”; 5′-GCG ATC TGG GCT CTG TGT TCT-3′, 0.2 μM of “P2 primer”; 5′-GTT 
CCC TGA GCC CCG ACA CG-3′, 10 mM Tris pH 8.8; 50 mM KCl and 1.5 mM 
of MgCl2.
Thermal cycles: A total of 35 thermal cycles was carried out with each cycle 
comprising DNA denaturation at 95°C for 1 min, primer annealing at 65°C for 1 min 
and primer extension at 72°C for 1 min; the initial denaturation was extended to 
5 min while the final extension was prolonged to 5 min.
Detection of amplified products: The amplified products were separated in 
2.5% agarose gel electrophoresis at 120 V for 15–20 min before visualizing with a 
UV-transilluminator. The fragments sizing 239 bp is the specific amplified prod-
ucts, and the PCR products sizing 314 bp are the control products (Figure 26).
Interpretation: Both M and N-reactions must have the 314-bp control products 
and the results can be read. If both M- and N-reactions have 239-bp PCR products, 
the samples are heterozygote for β17 with genotype of either β17/βA or β17/βT (A 
represents HbA; T represents other types of β-globin gene mutation). If the 239-bp 
PCR products are seen in only M-reaction, the samples are homozygote for β17 with 
genotype β17/β17. If samples have the 239-bp PCR products in only N-reaction, the 
samples are negative for the β17 with genotypes of either βA/βA or βT/βT (A represents 
HbA; T represents other types of β-globin gene mutation) (Figure 26).
Figure 25. 
ARMS-PCR for identifying the β41/42 mutation. The 314-bp amplified products are internal control. The 
439-bp amplified products are the β41/42 specific products. Sample #1 is homozygote for β41/42 mutation as the 
439-pb amplified products are seen in only “M-reaction.” Sample #3 is negative for the β41/42 mutation since 
the 439-bp amplified products are seen in only “N-reaction.” Sample #2 is heterozygote for the β41/42 mutation 
since the 439-bp amplified products are seen in both “M-reaction” and “N-reaction.”
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8.3 ARMS-PCR for βE
Procedure: Two 25-μL reactions are performed; M-reaction and N-reaction. 
Both M and N-reactions contain 150 ng genomic DNA, 200 μM of each dNTP; 
0.6 units Taq DNA polymerase, 0.2 μM of “S-primer”; 5′-ACC TCA CCC TGT GGA 
GCC AC-3′, 0.15 μM of “HbE-M primer”; 5′-TAA CCT TGA TAC CAA CCT GCC 
CAG GGC GTT-3′ (for M-reaction only), 0.15 μM of “HbE-N primer”; 5′-TAA CCT 
TGA TAC CAA CCT GCC CAG GGC GTC-3′ (for N-reaction only), 0.2 μM of “P1 
primer”; 5′-GCG ATC TGG GCT CTG TGT TCT-3′, 0.2 μM of “P2 primer”; 5′-GTT 
CCC TGA GCC CCG ACA CG-3′, 10 mM Tris pH 8.8; 50 mM KCl and 1.5 mM of 
MgCl2.
Thermal cycles: A total of 35 thermal cycles was carried out with each cycle 
comprising DNA denaturation at 95°C for 1 min, primer annealing at 65°C for 1 min 
and primer extension at 72°C for 1 min; the initial denaturation was extended to 
5 min while the final extension was prolonged to 5 min.
Detection of amplified products: The amplified products were separated in 
2.5% agarose gel electrophoresis at 120 V for 15–20 min before visualizing with a 
UV-transilluminator. The fragments sizing 260 bp is the specific amplified prod-
ucts, and the PCR products sizing 314 bp are the control products (Figure 27).
Figure 26. 
ARMS-PCR for identifying the β17 mutation. The 314-bp amplified products are internal control. The 239-bp 
amplified products are the β17 specific products. Sample #1 is homozygote for β17 mutation as the 239-pb amplified 
products are seen in only “M-reaction.” Sample #3 is negative for the β17 mutation since the 239-bp amplified 
products are seen in only “N-reaction.” Sample #2 is heterozygote for the β17 mutation since the 239-bp  
amplified products are seen in both “M-reaction” and “N-reaction.”
Figure 27. 
ARMS-PCR for identifying βE mutation. The 314-bp amplified products are internal control. The 260-bp 
amplified products are the βE specific products. Sample #3 is homozygote for βE mutation as the 260-pb amplified 
products are seen in only “M-reaction.” Sample #1 is negative for the βE mutation since the 260-bp amplified 
products are seen in only “N-reaction.” Sample #2 is heterozygote for the βE mutation since the 260-bp  
amplified products are seen in both “M-reaction” and “N-reaction.”
Beta Thalassemia
30
Interpretation: Both M and N-reactions must have the 314-bp control products 
and the results can be read. If both M- and N-reactions have 260-bp PCR products, 
the samples are heterozygote for βE with genotype of either βE/βA or βE/βT (A 
represents HbA; T represents other types of β-globin gene mutation). If the 260-bp 
PCR products are seen in only M-reaction, the samples are homozygote for βE with 
genotype βE/βE. If samples have the 260-bp PCR products in only N-reaction, the 
samples are negative for the βE with genotypes of either βA/βA or βT/βT (A represents 
HbA; T represents other types of β-globin gene mutation) (Figure 27).
9. Identification of β-thalassemia and HbE by MAS-PCR
This PCR technique was established by author and named multiplex allele spe-
cific (MAS)-PCR [29]. MAS was intended to be used for identifying βThalassemia and 
βE-mutations in samples that have already been diagnosed to be β-thalassemia carrier, 
HbE carrier, and SEA-α thalassemia 1 carrier. Therefore, only mutant primers are put 
together in this MAS-PCR. However, the internal control of this PCR protocol is the 
amplified products generated by the normal pair of primers for α-globin gene cluster.
Procedure: The PCR was performed in a total volume of 25 μL containing 
1.1–1.4 ng genomic DNA, 140 μM dNTPs, 0.1 unit/μL of DNA polymerase, 0.25 ng/
μL “Beta-common-multiplex” primer (5′-AAG AGC CAA GGA CAG GTA CGG 
CTG T-3′), 0.125 ng/μL “Beta-17-multiplex” primer (5′-CCA ACT TCA TCC ACG 
TTC ACG TA-3′), 0.125 ng/μL “Beta cds-41/42-multiplex” primer (5′-AGA TCC 
CCA AAG GAC TCA ACC T-3′), 0.125 ng/μL “Beta-E-multiplex” primer (5′-CGT 
ACC AAC CTG CCC AGG GCC AT-3′), 25 ng/μL “SEA-1-multiplex” primer (5′-
TGA CTC CAA TAA ATG GAT GAG GA-3′), 0.25 ng/μL “SEA-2-multiplex” primer 
(5′-GCC TGC GCC GGG GAA CGT AAC CA-3′)and 0.5 ng/μL “SEA-3-multiplex” 
primer (5′-CGC CAA AGA TGG CTA CTC GGA GA-3′) in 10 mM Tris-HCl 
(pH 8.8), 50 mM KCl, 2.0% DMSO and 2.0 mM MgCl2.
Thermal cycles: A total of 37 thermal cycles were carried out with each cycle 
comprising denaturation at 95°C for 1 min, primer annealing at 62°C for 30 s, and 
primer extension at 72°C for 30 s. Initial denaturation was extended to 5 min and 
final extension was prolonged to 7 min.
Detection of amplified products: The PCR products were separated via 
2.0% agarose gel electrophoresis and visualized by the UV-transilluminator 
(Figure 28).
Figure 28. 
MAS-PCR for identifying β-thalassemia mutation, βE-mutation, and SEA-α thalassemia 1 mutation. The 
653-bp amplified products are the internal control generated by the α-globin gene cluster specific oligonucleotide 
primers. Lanes 1–5 are positive for βE mutation as the 293-bp amplified products are seen. Lane 6 is positive for 
both SEA-α thalassemia 1 and βE mutations as both 753-bp amplified products and 293-bp amplified products 
are seen. Lane 7 is positive for both SEA-α thalassemia 1 and β17 mutation as both 753-bp amplified products 
and 268-bp amplified products are seen. Finally, lane 8 is positive for SEA-α thalassemia 1 and β41/42 mutation 
as both 753-bp amplified products and 466-bp amplified products are seen (modified from [82]).
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Interpretation: All reactions must have the 653-bp control products. Presence of 753-
bp product indicates presence of the SEA-α thalassemia 1. Presence of the 466-bp, 293-
bp, and 268-bp products indicates presence of β41/42, βE, and β17, respectively (Figure 28).
10. Pitfalls in laboratory diagnosis of β-thalassemia and HbE
There are several pitfalls to be concerned when using laboratory data in diagno-
sis of β-thalassemia and HbE. The pitfalls are in both screening and confirmatory 
steps of laboratory diagnosis.
HbE tube test relies on concentration of NaCl. Therefore, exact amount of NaCl 
in the reagent must be prepared following the suggested ingredient. False positive 
results will be obtained if NaCl concentration is too high, and vice versa.
HbE screen test relies on pH-based microcolumn chromatography. Therefore, 
exact pH of buffer in the test kit must also be prepared. Too high pH causes falsely 
negative results and vice versa.
10.1 Pitfalls in screening tests for β-thalassemia and HbE carriers
1. Pitfalls in one-tube osmotic fragility test (OFT). The concentration of reagent 
must be exactly 0.36 and 0.45%, otherwise false positive results will be obtained 
if concentration is over 0.36 or over 0.45%. In contrast, false negative results 
will be obtained if concentration is less than 0.36 or 0.45%. Anemic blood sam-
ples will also give positive results. Therefore, Hb/Hct must also be checked if the 
results are positive. Not all HbE carriers have positive OFT results. Therefore, 
blood samples having negative OFT results must also be sent for HbE screen.
2. Pitfalls in MCV and MCH evaluation. MCV/MCH are the numeric data that 
must be obtained from automated blood cell counters that have good quality 
control. MCV must be obtained using fresh blood, but MCH may be obtained 
using 1 week-old blood. MCV is directly measured in automated blood coun-
ter, while MCH is generated by calculation. Thus, if blood samples have high 
degree of variation of red blood cell sizes or anisocytosis, false MCV values 
may be obtained. This situation may be found in β-thalassemia carriers or HbE 
carriers with co-existence iron deficiency anemia during treatment. Not all 
HbE carriers have MCV/MCH values below cutoff points. Therefore, all blood 
samples sent for MCV/MCH determination must also be sent for HbE screen. 
Most importantly, some blood samples may have discordant MCV-OFT results. 
It is then highly recommended to perform both OFT and MCV/MCH for 
screening for β-thalassemia and HbE carriers.
3. Pitfalls in HbE screening test. DCIP test is based on using the oxidizing re-
agent; dichlorophenolindophenol. This reagent can be reduced over long storage 
and the screening results will be falsely negative. Therefore, if color of the DCIP 
reagent turns deeply blue, it should not be used. HbH also denatured in the DCIP 
reagent. Therefore, positive samples must be checked if they are HbH disease.
10.2 Pitfalls in confirmatory tests for β-thalassemia and HbE
Normal hemoglobin type depends on age of the patients. Thus, reading and 
interpreting the hemoglobin typing results by all methodologies, age of the patients 
must be taken into account. In addition, transfused blood interferes the real 
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hemoglobin typing results of the patients. If the patients of β-thalassemia disease 
(βO/βO) have just received blood transfusion, their hemoglobin types will be A2AF, 
instead of A2F which is the real hemoglobin type of the β
O/βO. If patients of HbE/
βO-thalassemia (βE/βO) have recent blood transfusion, their hemoglobin types will 
be EFA, instead of EF which is the real hemoglobin type of βO/βE. Therefore, recent 
blood transfusion should always be taken into account when reading and interpret-
ing the hemoglobin typing results.
Co-existence of α-thalassemia 1 in β-thalassemia carrier and in HbE carrier can 
be found some regions. This is called double α-thalassemia 1/β-thalassemia carriers 
and double α-thalassemia 1 and HbE carriers. Results of one-tube osmotic fragility 
test are always positive in double α-thalassemia 1/β-thalassemia carriers, being the 
same as that of the single β-thalassemia carrier. However, MCV/MCH in double 
α-thalassemia 1/β-thalassemia carriers are slightly higher than those in the single 
β-thalassemia carriers (70.7 ± 2.6 vs. 68.4 ± 2.7 for MCV, 21.0 ± 1.2 vs. 20.7 ± 0.9 for 
MCH) [83]. HbA2 level in double α-thalassemia 1/β-thalassemia carriers is lower 
than that in single β-thalassemia carrier (5.27 ± 0.77% vs. 5.65 ± 0.78%) [29]. In 
contrast, the results of one-tube osmotic fragility test of double α-thalassemia 1/
HbE carrier are usually positive, being different from those of single HbE which 
can be either positive or negative. The MCV/MCH in double α-thalassemia 1/
HbE carrier are lower than those of the single HbE carrier (68.7 ± 8.9 fL vs. 
75.7 ± 7.5 fL for MCV, 22.5 ± 3.1 pg vs. 24.9 ± 2.8 pg for MCH). HbE level in double 
α-thalassemia 1/HbE carrier are lower than those of the single HbE carrier 
(22.8 ± 4.4% vs. 27.6 ± 3.3%) [84]. Therefore, if HbE carriers have low HbE levels 
as well as MCV/MCH, further identification of α-thalassemia 1 genotype must be 
done.
11. Conclusions
Diagnosis of β-thalassemia and HbE requires laboratory investigations. 
Screening tests are used to search for carriers, while confirmatory tests are carried 
out in those samples positive for screening tests with the aim to make the definite 
diagnosis. There are several pitfalls in these laboratory tests, both in screening tests 
and confirmatory tests that must not be overlooked, otherwise misdiagnosis will 
occur.
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